Specific targeting cytotoxicity to resistant leukemia cells mediated by anti-Pgp/anti-CD3 diabody.
- Author:
Ying-dai GAO
1
;
Dong-sheng XIONG
;
Ming YANG
;
Yuan-fu XU
;
Xiao-feng SHAO
;
Hui PENG
;
Dong-mei FAN
;
Chun-zheng YANG
Author Information
- Publication Type:Journal Article
- MeSH: ATP-Binding Cassette, Sub-Family B, Member 1; immunology; Animals; Antibodies, Bispecific; immunology; pharmacology; CD3 Complex; immunology; Cytotoxicity, Immunologic; drug effects; Drug Resistance, Neoplasm; immunology; Humans; Jurkat Cells; Mice; Mice, Nude; T-Lymphocytes; drug effects; immunology; Xenograft Model Antitumor Assays
- From: Chinese Journal of Hematology 2005;26(6):342-344
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the specific targeting cytotoxicity to drug-resistant leukemia cells mediated by anti-Pgp/anti-CD3 diabody.
METHODSThe diabody was purified by affinity chromatography and identified by SDS-PAGE and FACS. The effect of the anti-Pgp/anti-CD3 diabody mediated lysis of Pgp-expressing tumor cells was assayed by human leukemia nude mice xenograft model in vivo.
RESULTSThe diabody was produced in E.coli in a soluble functional form and could bind both Jurkat cells (CD3(+)) and K562/A02 cells (Pgp(+)). The binding rates were 86.25% and 86.26%, respectively. It could inhibit tumor growth by 98.57% and prolonged the survival of mice bearing xenografted K562/A02 cells.
CONCLUSIONThe diabody was proved to be a potent agent for mediating T lymphocyte cytotoxicity to lyse Pgp expressing tumor cells in vitro and in vivo.
